Sobi board recommends shareholders accept takeover offer

3 September 2021

Shares of Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, jumped as much as 23.6% to 235 Swedish kronor early today, after the company revealed it has received a takeover bid.

Advent International Corporation and Aurora Investment Pte Ltd, an affiliate of GIC Pte Ltd, through Agnafit Bidco AB have today announced a public cash offer to Sobi’s shareholders to transfer their shares in Sobi to Agnafit Bidco. Under the terms of the offer, Agnafit Bidco will pay 235 kronor per Sobi share in cash, which values the issued share capital of Sobi at around 69.4 billion kronor (~$8.0 billion).

According to Sobi, the offer price represents a premium of:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK